United Therapeutics (UTHR) Q1 2026 earnings review
Pipeline Triumphs While the Commercial Engine Stalls
United Therapeutics delivered on its biggest long-term promises but stumbled hard in the present. The company announced positive readouts for its massive TETON-1 (IPF) and ADVANCE OUTCOMES (PAH) trials, derisking its path to a $4 billion revenue run rate. However, Q1 2026 financials reveal a sharply reversing commercial trend: Total revenue fell 2% YoY to $781.5M, breaking a multi-year growth streak. The core Tyvaso franchise shrank as a 22% collapse in nebulized sales outweighed a decelerating 9% growth in DPI. Compounding the top-line miss, Net Income plunged 15% due to a shocking $26.8M inventory reserve charge. Management is deploying a massive $1.5B Accelerated Share Repurchase (ASR) to cushion the blow, but the divergence between strong clinical data and deteriorating commercial execution is glaring.
🐂 Bull Case
Positive readouts from both TETON-1 and ADVANCE OUTCOMES secure the company's two largest future growth drivers, validating management's aggressive 2027 pipeline narrative.
The execution of a $1.5B ASR in a single quarter (retiring ~2.16M shares) provides a massive floor for the stock and synthetically supports EPS during a period of commercial transition.
🐻 Bear Case
Total Tyvaso sales declined 2% YoY. A 22% plunge in the nebulized version and decelerating DPI growth directly contradict management's previous claims that competitor launches (like Liquidia's Yutrepia) were having 'no material impact'.
Cost of sales skyrocketed 44% YoY driven by a $26.8M inventory reserve charge for Tyvaso DPI. If manufacturing or supply agreements are penalizing the company amidst slowing demand, margins will remain pressured.
⚖️ Verdict: ⚪
Neutral. The commercial miss is highly concerning and completely shatters the 'durable double-digit growth' narrative promoted heavily in late 2025. However, the successful readouts of TETON-1 and ADVANCE OUTCOMES are monumental achievements that preserve the company's long-term terminal value.
Key Themes
The Unthinkable: Tyvaso Revenues Reverse
The cornerstone of UTHR's growth engine is sputtering. Total Tyvaso revenues reversed, falling 2% YoY to $457.5M. While Tyvaso DPI grew 9% YoY (a significant deceleration from the 20%+ growth rates seen in mid-2025), Nebulized Tyvaso collapsed 22% to $127.2M (down $36.6M). This volume loss suggests that competitive pressures—likely from Liquidia's Yutrepia—are inflicting real damage, contradicting management's intensely defensive posture in Q3/Q4 2025 where they claimed 'no material impact.'
Pipeline Holy Grail Realized
Management announced positive results for both the ADVANCE OUTCOMES (Ralinepag) and TETON-1 (Tyvaso in IPF) studies. These are not incremental updates; they are the two binary events the entire bull thesis rested upon. This secures the path for an IPF label expansion (doubling the addressable market) and introduces a true once-daily oral prostacyclin. This validates the 'Innovation Wave' and supports the $4B run-rate target.
Gross Margin Shock from Inventory Reserves
Cost of Sales surged 44% YoY (+$40.9M), severely depressing operating leverage. The primary driver was a $26.8M inventory reserve charge tied to an 'estimated loss from a commercial supply agreement' for Tyvaso DPI. Investors must question whether UTHR was forced to eat minimum-purchase penalties because DPI demand decelerated below their internal forecasts.
Orenitram Remains a Pillar of Stability
Amidst the Tyvaso chaos, Orenitram provided a critical backstop. Revenues accelerated 12% YoY to $135.6M, driven by a $10.2M increase in quantities sold. This demonstrates sticky prescriber habits and continued benefits from the Medicare Part D benefit redesign.
Other KPIs
Reversing. A massive 44% YoY increase from $92.5M in 25Q1, entirely decoupling from the 2% drop in revenue. This destroyed gross margin profile in the quarter, largely due to the $26.8M DPI supply agreement loss.
Decelerating. Decreased 7% YoY, primarily due to a $19.9M reduction in 'Other' expenses (fewer upfront milestones for device technologies compared to Q1 2025). Internal R&D actually increased 21% to $58.3M.
Accelerating. The Board authorized a new $2.0B program in March 2026, and the company immediately entered a $1.5B ASR with Citibank, receiving 2.16M shares in Q1 alone. $500M remains available. This synthetic EPS support is crucial while the top line temporarily stalls.
Guidance
Management explicitly committed to returning to sequential quarterly revenue growth across the commercial portfolio. Given Q1 2026 printed at $781.5M, this implies Q2 2026 must be higher, putting immediate pressure on commercial execution.
Key Questions
Inventory Reserve Specifics
Can you provide exact details on the $26.8M Tyvaso DPI inventory reserve? Does this reflect minimum-purchase commitments that were missed due to slowing demand, or is it related to product expiry/manufacturing defects?
Reconciling Tyvaso Weakness with Past Commentary
In Q4 you noted 'no material impact' from competitors and robust referral rates. Yet Nebulized Tyvaso fell 22% YoY and DPI growth decelerated to 9%. Is this entirely due to Yutrepia, or are there underlying PAH market destocking/seasonality dynamics at play?
TETON-1 and ADVANCE OUTCOMES Filings
With the positive readouts confirmed, what is the precise timeline for NDA submissions and expected FDA action dates for both the IPF indication and Ralinepag?
Ralinepag DPI Development
You announced development plans for a Ralinepag DPI. What are the expected R&D costs associated with this program, and does it push out the timeline for recognizing Ralinepag revenues compared to the oral formulation?